FDA grants pri­or­i­ty re­views for Pfiz­er's Pre­vnar 20 for kids and Roche lym­phoma can­di­date

The FDA grant­ed two pri­or­i­ty re­views: one for a po­ten­tial Pfiz­er vac­cine for kids and the oth­er for Roche’s bis­pe­cif­ic an­ti­body glofi­ta­m­ab, the com­pa­nies an­nounced …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER